Randomized study of repaglinide alone and in combination with metformin in Chinese subjects with type 2 diabetes naive to oral antidiabetes therapy

Expert Opinion on Pharmacotherapy

Volumn 12, Issue 18, 2011, Pages 2791-2799

  Wang, Weiqing ^a   Bu, Ruifang ^b   Su, Qing ^c   Liu, Jianying ^d   Ning, Guang ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b Wuxi First People's Hospital   (China)

^c SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^d NANCHANG UNIVERSITY   (China)

Author keywords

China; Combination therapy; Metformin; Oral antidiabetes drugs (OADs); Repaglinide; Type 2 diabetes

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; METFORMIN; REPAGLINIDE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CHINESE; COMBINATION CHEMOTHERAPY; DIARRHEA; DIZZINESS; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; FATIGUE; FEMALE; GASTROINTESTINAL DISEASE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEART DISEASE; HEART RIGHT BUNDLE BRANCH BLOCK; HEPATOBILIARY DISEASE; HUMAN; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; HYPOGLYCEMIA; INFECTION; INFESTATION; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MONOTHERAPY; MULTICENTER STUDY; NEUROLOGIC DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NUTRITIONAL DISORDER; OPEN STUDY; PARALLEL DESIGN; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; SKIN DISEASE; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; UPPER RESPIRATORY TRACT INFECTION;

ADOLESCENT; ADULT; AGED; BLOOD GLUCOSE; CARBAMATES; CHINA; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; PIPERIDINES; YOUNG ADULT;

EID: 81855206490     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2011.602341     Document Type: Article

References (26)

1. Yang W, Lu J, Weng J, et al. Prevalence of diabetes among men and women in China. N Engl J Med 2010;362:1090-101
2. Pan XR, Yang WY, Li GW, et al. Prevalence of diabetes and its risk factors in China, 1994. National Diabetes Prevention and Control Cooperative Group. Diabetes Care 1997;20:1664-9
3. Chan JC, Deerochanawong C, Shera AS, et al. Role of metformin in the initiation of pharmacotherapy for type 2 diabetes: an Asian-Pacific perspective. Diabetes Res Clin Pract 2007;75:255-66
4. Asian-Pacific Type 2 Diabetes Policy Group. Type 2 diabetes: practical targets and treatments. 4th edition. Available from: http://www.diabetes.com.au/ pdf/ Diabetes-TreatmentTargets-FINAL.pdf [Last accessed 14 June 2011]
5. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32:193-203
6. Chan JC, Malik V, Jia W, et al. Diabetes in Asia: epidemiology, risk factors, and pathophysiology. JAMA 2009;301:2129-40
7. Chinese Diabetes Society. The Chinese type 2 diabetes guideline: Chinese diabetes society. Zhonghua Yi Xue Za Zhi 2008;88:1227-45
8. Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/ American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 2009;15:540-59
9. Moses R, Slobodniuk R, Boyages S, et al. Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 1999;22:119-24
10. US Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for Industry. Diabetes mellitus: developing drugs and therapeutic biologics for treatment and prevention. Available from: http://www.fda.gov/ downloads/ Drugs/GuidanceComplianceRegulatory Information/Guidances/ucm071624. pdf [Last accessed 14 June 2011]
11. American Diabetes Association. Standards of medical care in diabetes - 2011. Diabetes Care 2011;34(Suppl 1):S11-61
12. International Diabetes Federation. Global guideline for type 2 diabetes. Available from: http://www.idf.org/ Global-guideline [Last accessed 14 June 2011]
13. Lund SS, Tarnow L, Stehouwer CD, et al. Targeting hyperglycaemia with either metformin or repaglinide in non-obese patients with type 2 diabetes: results from a randomized crossover trial. Diabetes Obes Metab 2007;9:394-407
14. UK Prospective Diabetes Study Group. UK Prospective Diabetes Study (UKPDS): VIII. Study design, progress and performance. Diabetologia 1991;34:877-90
15. Raskin P. Oral combination therapy: repaglinide plus metformin for treatment of type 2 diabetes. Diabetes Obes Metab 2008;10:1167-77
16. Papa G, Fedele V, Rizzo MR, et al. Safety of type 2 diabetes treatment with repaglinide compared with glibenclamide in elderly people: a randomized, open-label, two-period, cross-over trial. Diabetes Care 2006;29:1918-20
17. Derosa G, Mugellini A, Ciccarelli L, et al. Comparison between repaglinide and glimepiride in patients with type 2 diabetes mellitus: a one-year, randomized, double-blind assessment of metabolic parameters and cardiovascular risk factors. Clin Ther 2003;25:472-84
18. He J, Gu D, Wu X, et al. Major causes of death among men and women in China. N Engl J Med 2005;353:1124-34
19. Hanefeld M, Fischer S, Julius U, et al. Risk factors for myocardial infarction and death in newly detected NIDDM: the diabetes intervention study, 11-year follow-up. Diabetologia 1996;39:1577-83
20. DECODE Study Group, European Diabetes Epidemiology Group. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 2001;161:397-405
21. Tibaldi J. Importance of postprandial glucose levels as a target for glycemic control in type 2 diabetes. South Med J 2009;102:60-6
22. Esposito K, Giugliano D, Nappo F, et al. Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus. Circulation 2004;110:214-19
23. Bailey CJ, Del PS, Eddy D, et al. Earlier intervention in type 2 diabetes: the case for achieving early and sustained glycaemic control. Int J Clin Pract 2005;59:1309-16
24. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34).Lancet 1998;352:854-65
25. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-12
26. Brown JB, Nichols GA, Perry A. The burden of treatment failure in type 2 diabetes. Diabetes Care 2004;27:1535-40